Mitochondrial complex I inhibitor rotenone inhibits and redistributes vesicular monoamine transporter 2 via nitration in human dopaminergic SH-SY5Y cells

Molecular Pharmacology

Volumn 74, Issue 4, 2008, Pages 933-940

  Watabe, Masahiko ^a   Nakaki, Toshio ^a  

^a TEIKYO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ANTIBODY; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; VESICULAR MONOAMINE TRANSPORTER 2;

APOPTOSIS; ARTICLE; CELL LINE; CONTROLLED STUDY; CYTOSOL; DOPAMINERGIC NERVE CELL; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOPRECIPITATION; NITRATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN LOCALIZATION;

APOPTOSIS; CELL LINE, TUMOR; CYTOSOL; DNA FRAGMENTATION; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRON TRANSPORT COMPLEX I; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HUMANS; MITOCHONDRIA; NEUROBLASTOMA; NG-NITROARGININE METHYL ESTER; NITROGEN; PIPERAZINES; ROTENONE; TIME FACTORS; TYROSINE; UNCOUPLING AGENTS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 52949101301     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.048546     Document Type: Article

References (39)

1. Ara J, Przedborski S, Naini AB, Jackson-Lewis V, Trifiletti RR, Horwitz J, and Ischiropoulos H (1998) Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP). Proc Natl Acad Sci U S A 95:7659-7663.
2. Beckman JS (1994) Peroxynitrite versus hydroxyl radical: the role of nitric oxide in superoxide-dependent cerebral injury. Ann N Y Acad Sci 738:69-75.
3. Beckman JS and Koppenol WH (1996) Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 271:C1424-C1437.
4. Blanchard-Fillion B, Souza JM, Friel T, Jiang GC, Vrana K, Sharov V, Barrón L, Schöneich C, Quijano C, Alvarez B, et al. (2001) Nitration and inactivation of tyrosine hydroxylase by peroxynitrite. J Biol Chem 276:46017-46023.
5. Brunk I, Blex C, Rachakonda S, Höltje M, Winter S, Pahner I, Walther DJ, and Ahnert-Hilger G (2006) The first luminal domain of vesicular monoamine transporters mediates G-protein-dependent regulation of transmitter uptake. J Biol Chem 281:33373-33385.
6. Dawson TM and Dawson VL (2003) Molecular pathways of neurodegeneration in Parkinson's disease. Science 302:819-822.
7. Erickson JD, Eiden LE, and Hoffman BJ (1992) Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc Natl Acad Sci U S A 89:10993-10997.
8. Finn JP 3rd and Edwards RH (1997) Individual residues contribute to multiple differences in ligand recognition between vesicular monoamine transporters 1 and 2. J Biol Chem 272:16301-16307.
9. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, and Lee VM (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290:985-989.
10. Good PF, Hsu A, Werner P, Perl DP, and Olanow CW (1998) Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol 57:338-342.
11. Greenamyre JT, Sherer TB, Betarbet R, and Panov AV (2001) Complex I and Parkinson's disease. IUBMB Life 52:135-141.
12. Halliwell B (1992) Reactive oxygen species and the central nervous system. J Neurochem 59:1609-1623.
13. Harrington KA, Augood SJ, Kingsbury AE, Foster OJ, and Emson PC (1996) Dopamine transporter (Dat) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson's disease. Brain Res Mol Brain Res 36:157-162.
14. He Y, Imam SZ, Dong Z, Jankovic J, Ali SF, Appel SH, and Le W (2003) Role of nitric oxide in rotenone-induced nigro-striatal injury. J Neurochem 86:1338-1345.
15. Höltje M, von Jagow B, Pahner I, Lautenschlager M, Hörtnagl H, Nürnberg B, Jahn R, and Ahnert-Hilger G (2000) The neuronal monoamine transporter VMAT2 is regulated by the trimeric GTPase Go(2). J Neurosci 20:2131-2141.
16. Ischiropoulos H and al-Mehdi AB (1995) Peroxynitrite-mediated oxidative protein modifications. FEBS Lett 364:279-282.
17. Ischiropoulos H, Zhu L, Chen J, Tsai M, Martin JC, Smith CD, and Beckman JS (1992) Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch Biochem Biophys 298:431-437.
18. Kanner BI and Schuldiner S (1987) Mechanism of transport and storage of neurotransmitters. CRC Crit Rev Biochem 22:1-38.
19. Koppenol WH, Moreno JJ, Pryor WA, Ischiropoulos H, and Beckman JS (1992) Peroxynitrite, a cloaked oxidant formed by nitric oxide and superoxide. Chem Res Toxicol 5:834-842.
20. Kuhn DM, Sakowski SA, Sadidi M, and Geddes TJ (2004) Nitrotyrosine as a marker for peroxynitrite-induced neurotoxicity: the beginning or the end of the end of dopamine neurons? J Neurochem 89:529-536.
21. Li N, Ragheb K, Lawler G, Sturgis J, Rajwa B, Melendez JA, and Robinson JP (2003) Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J Biol Chem 278:8516-8525.
22. Liu Y, Peter D, Roghani A, Schuldiner S, Privé GG, Eisenberg D, Brecha N, and Edwards RH (1992) A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell 70:539-551.
23. Miller GW, Erickson JD, Perez JT, Penland SN, Mash DC, Rye DB, and Levey AI (1999) Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp Neurol 156:138-148.
24. Nakashima S and Ikuta F (1984) Tyrosine hydroxylase protein in Lewy bodies of parkinsonian and senile brains. J Neurol Sci 66:91-96.
25. Nirenberg MJ, Chan J, Liu Y, Edwards RH, and Pickel VM (1996) Ultrastructural localization of the vesicular monoamine transporter-2 in midbrain dopaminergic neurons: potential sites for somatodendritic storage and release of dopamine J Neurosci 16:4135-4145.
26. Peter D, Liu Y, Sternini C, de Giorgio R, Brecha N, and Edwards RH (1995) Differential expression of two vesicular monoamine transporters. J Neurosci 15: 6179-6188.
27. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, and Marsden CD (1990) Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54:823-827.
28. Shastry BS (2001) Parkinson disease: etiology, pathogenesis and future of gene therapy. Neurosci Res 41:5-12.
29. Souza JM, Daikhin E, Yudkoff M, Raman CS, and Ischiropoulos H (1999) Factors determining the selectivity of protein tyrosine nitration. Arch Biochem Biophys 371:169-178.
30. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, and Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388:839-840.
31. Trimmer PA, Borland MK, Keeney PM, Bennett JP Jr, and Parker WD Jr (2004) Parkinson's disease transgenic mitochondrial cybrids generate Lewy inclusion bodies. J Neurochem 88:800-812.
32. Watabe M, Hishikawa K, Takayanagi A, Shimizu N, and Nakaki T (2004) Caffeic acid phenethyl ester induces apoptosis by inhibition of NFκB and activation of Fas in human breast cancer MCF-7 cells. J Biol Chem 279:6017-6026.
33. Watabe M, Ito K, Masuda Y, Nakajo S, and Nakaya K (1998) Activation of AP-1 is required for bufalin-induced apoptosis in human leukemia U937 cells. Oncogene 16:779-787.
34. Watabe M, Machida K, and Osada H (2000) MT-21 is a synthetic apoptosis inducer that directly induces cytochrome c release from mitochondria. Cancer Res 60:5214-5222.
35. Watabe M, Nakajo S, Yoshida T, Kuroiwa Y, and Nakaya K (1997) Treatment of U937 cells with bufalin induces the translocation of casein kinase 2 and modulates the activity of topoisomerase II prior to the induction of apoptosis. Cell Growth Differ 8:871-879.
36. Watabe M and Nakaki T (2004) Rotenone induces apoptosis via activation of bad in human dopaminergic SH-SY5Y cells. J Pharmacol Exp Ther 311:948-953.
37. Watabe M and Nakaki T (2007) Mitochondrial complex I inhibitor rotenone-elicited dopamine redistribution from vesicles to cytosol in human dopaminergic SH-SY5Y cells. J Pharmacol Exp Ther 323:499-507.
38. Weinreb O, Mandel S, and Youdim MB (2003) cDNA gene expression profile homology of antioxidants and their antiapoptotic and proapoptotic activities in human neuroblastoma cells. FASEB J 17:935-937.
39. Yamamoto S, Fukae J, Mori H, Mizuno Y, and Hattori N (2006) Positive immunoreactivity for vesicular monoamine transporter 2 in Lewy bodies and Lewy neurites in substantia nigra. Neurosci Lett 396:187-191.